Clinical trial
A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or…
NCT00317642 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00317642 |
|---|---|
| Title | A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) |
| Official title | A Phase III Randomized, Double-blind, Controlled Study Comparing Clofarabine and Cytarabine Versus Cytarabine Alone in Adult Patients 55 Years and Older With Acute Myelogenous Leukemia (AML) Who Have Relapsed or Are Refractory After Receiving up to Two Prior Induction Regimens |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | clofarabine (IV formulation), placebo, cytarabine |
| Enrollment | 326 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Apr 25, 2006 |
| Last update posted | Apr 14, 2014 |
| Countries | Canada, France, Germany, Italy, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: